Revolution Medicines, Inc.
RVMDW· Nasdaq
RVMDWRevolution Medicines, Inc.
Filed Nov 12, 2020 · 10-Q · 43 days after period end · 0001564590-20-053333
| Metric | Q3 2020 | Q3 2019 |
|---|---|---|
| Revenue | $12.66M | $12.51M |
| Net Income | -$27.22M | -$12.82M |
| EPS Diluted | -$0.42 | -$6.08 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Revolution Medicines, Inc. · CIK 1628171 · Engraved from SEC EDGAR
ended Sep 30, 2020 · filed Nov 12, 2020 · 43 d after period end
